Dieter Kabelitz

List of Publications by Year
in descending order

137	6,405	50276	79698
papers	citations	46 h-index	73 g-index

169	169	169	6508
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells. OncoImmunology, 2022, 11, 2030021.	4.6	7
2	Accelerated co-cultured dendritic cell (acDC) loaded with autologous apoptotic bodies might be a promising approach for antigen delivery. Journal of Immunoassay and Immunochemistry, 2022, , 1-13.	1.1	0
3	Lower frequency of T stem cell memory (TSCM) cells in hepatitis B vaccine nonresponders. Immunologic Research, 2022, 70, 469-480.	2.9	1
4	A MÃ©nage Ã Trois of Cytotoxic Effector Cells: Î³Î´ T Cells Suppress NK Cells but Not CTLs. Cancer Immunology Research, 2022, , OF1-OF1.	3.4	1
5	Analysis of the Seasonal Fluctuation of Î³Î´ T Cells and Its Potential Relation with Vitamin D3. Cells, 2022, 11, 1460.	4.1	6
6	Immune surveillance in glioblastoma: Role of the <scp>NKG2D</scp> system and novel cellâ€based therapeutic approaches. Scandinavian Journal of Immunology, 2022, 96, .	2.7	13
7	Vitamin C and Vitamin Dâ€"friends or foes in modulating Î³Î´ T-cell differentiation?. , 2022, 19, 1198-1200.		2
8	Allogeneic VÎ³9VÎ´2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cellular and Molecular Immunology, 2021, 18, 427-439.	10.5	122
9	DNA methylation profile of a hepatosplenic gamma/delta T-cell lymphoma patient associated with response to interferon-Î± therapy. Cellular and Molecular Immunology, 2021, 18, 1332-1335.	10.5	1
10	Reply to: Vitamin C as a promoter of Î³Î´ T cells. Cellular and Molecular Immunology, 2021, 18, 495-495.	10.5	0
11	Erroneous expression of NKG2D on granulocytes detected by phycoerythrinâ€conjugated clone 149810 antibody. Cytometry Part B - Clinical Cytometry, 2021, , .	1.5	4
12	Proportion of T follicular helper cells in peripheral blood of rheumatoid arthritis patients: a systematic review and meta-analysis. Expert Review of Clinical Immunology, 2021, 17, 667-680.	3.0	5
13	Monocyte-dependent co-stimulation of cytokine induction in human Î³Î´ T cells by TLR8 RNA ligands. Scientific Reports, 2021, 11, 15231.	3.3	5
14	Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis. Archives of Virology, 2021, 166, 2469-2478.	2.1	6
15	A welcome of the Immunologic Researchâ€™s new editors. Immunologic Research, 2021, 69, 307-308.	2.9	0
16	Targeting citrate carrier (CIC) in inflammatory macrophages as a novel metabolic approach in COVID-19 patients: A perspective. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	1.2	3
17	Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen. Biological Chemistry, 2021, .	2.5	6
18	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?. Frontiers in Immunology, 2021, 12, 765906.	4.8	12

#	Article	IF	Citations
19	Vitamin C promotes the proliferation and effector functions of human Î³Î´ T cells. Cellular and Molecular Immunology, 2020, 17, 462-473.	10.5	68
20	Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4. Cellular and Molecular Life Sciences, 2020, 77, 751-764.	5.4	15
21	Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. Journal of Leukocyte Biology, 2020, 107, 1081-1095.	3.3	35
22	Tumor resistance mechanisms and their consequences on Î³Î´ T cell activation. Immunological Reviews, 2020, 298, 84-98.	6.0	33
23	Editorial: Î³Î´ T Cells in Cancer. Frontiers in Immunology, 2020, 11, 602411.	4.8	2
24	The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. Frontiers in Immunology, 2020, 11, 1582.	4.8	228
25	Cancer immunotherapy with Î³Î´ T cells: many paths ahead of us. Cellular and Molecular Immunology, 2020, 17, 925-939.	10.5	180
26	Gamma Delta T Cells (Î³Î´ T Cells) in Health and Disease: In Memory of Professor Wendy Havran. Cells, 2020, 9, 2564.	4.1	8
27	Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on Î³Î´ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells. Cells, 2020, 9, 1140.	4.1	31
28	An introduction to immunology and epigenetics. , 2020, , 1-23.		1
29	Activation of Human Î³Î´ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes. Cells, 2020, 9, 713.	4.1	18
30	Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses Î³Î´ T Cell Proliferation but Not Their Cytotoxicity. Frontiers in Immunology, 2020, 11, 1328.	4.8	16
31	A comparative view on vitamin C effects on Î±Î²â€•versus Î³Î´ Tâ€cell activation and differentiation. Journal of Leukocyte Biology, 2020, 107, 1009-1022.	3.3	10
32	Early HIV infection is associated with reduced proportions of gamma delta T subsets as well as high creatinine and urea levels. Scandinavian Journal of Immunology, 2020, 91, e12868.	2.7	7
33	In vitro expansion of VÎ³9VÎ2 T cells for immunotherapy. Methods in Enzymology, 2020, 631, 223-237.	1.0	13
34	Real-time cell analysis (RTCA) to measure killer cell activity against adherent tumor cells in vitro. Methods in Enzymology, 2020, 631, 429-441.	1.0	14
35	Pitfalls in the characterization of circulating and tissue-resident human Î³Î´ T cells. Journal of Leukocyte Biology, 2020, 107, 1097-1105.	3.3	12
36	Vitamin C supports conversion of human Î³Î´ T cells into FOXP3-expressing regulatory cells by epigenetic regulation. Scientific Reports, 2020, 10, 6550.	3.3	25

#	Article	IF	Citations
37	Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells. Frontiers in Immunology, 2019, 10, 1690.	4.8	71
38	Immunology Education Without Borders. Frontiers in Immunology, 2019, 10, 2012.	4.8	6
39	TRAIL-Receptor 4 Modulates Î³Î´ T Cell-Cytotoxicity Toward Cancer Cells. Frontiers in Immunology, 2019, 10, 2044.	4.8	32
40	Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells. Frontiers in Immunology, 2019, 10, 569.	4.8	22
41	Influence of forkhead box protein 3 polymorphisms (rs2232365, rs3761548) with the outcome of pregnancy: A metaâ€anâ€alysis. Journal of Cellular Physiology, 2019, 234, 16573-16581.	4.1	16
42	An update on immune dysregulation in obesityâ€related insulin resistance. Scandinavian Journal of Immunology, 2019, 89, e12747.	2.7	61
43	Granulysin species segregate to different lysosome-related effector vesicles (LREV) and get mobilized by either classical or non-classical degranulation. Molecular Immunology, 2019, 107, 44-53.	2.2	12
44	DNA methylation profiling of hepatosplenic T-cell lymphoma. Haematologica, 2019, 104, e104-e107.	3.5	11
45	TGF-Î² enhances the cytotoxic activity of VÎ´2 T cells. OncoImmunology, 2019, 8, e1522471.	4.6	43
46	Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut, 2019, 68, 25-39.	12.1	160
47	Pyrin and Hematopoietic Interferon-Inducible Nuclear Protein Domain Proteins: Innate Immune Sensors for Cytosolic and Nuclear DNA. Critical Reviews in Immunology, 2019, 39, 275-288.	0.5	3
48	Regulatory functions of Î³Î´ T cells. Cellular and Molecular Life Sciences, 2018, 75, 2125-2135.	5.4	60
49	Mechanistic peculiarities of activation-induced mobilization of cytotoxic effector proteins in human T cells. International Immunology, 2018, 30, 215-228.	4.0	11
50	NKG2D ligands in glioma stem-like cells: expression in situ and in vitro. Histochemistry and Cell Biology, 2018, 149, 219-233.	1.7	27
51	Multilayer epigenetic analysis reveals novel transcription factor networks in CD8 T cells. Cellular and Molecular Immunology, 2018, 15, 199-202.	10.5	3
52	Predicting Humoral Alloimmunity from Differences in Donor and Recipient HLA Surface Electrostatic Potential. Journal of Immunology, 2018, 201, 3780-3792.	0.8	47
53	The Î³Î´TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. Nature Immunology, 2018, 19, 1352-1365.	14.5	163
54	Immunotherapy With Human Gamma Delta T Cellsâ€"Synergistic Potential of Epigenetic Drugs?. Frontiers in Immunology, 2018, 9, 512.	4.8	11

#	Article	IF	Citations
55	Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing Î³Î´ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. Frontiers in Immunology, 2018, 9, 814.	4.8	84
56	P371 Vedolizumab is associated with changes in innate rather than T-cell immunity in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2018, 12, S292-S292.	1.3	0
57	The Influence of MHC Class II on B Cell Defects Induced by Invariant Chain/CD74 N-Terminal Fragments. Journal of Immunology, 2017, 199, 172-185.	0.8	11
58	Environmental factor and inflammation-driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitis. Journal of Autoimmunity, 2017, 78, 79-91.	6.5	34
59	In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. OncoImmunology, 2017, 6, e1358839.	4.6	37
60	CD20â€Specific Immunoligands Engaging NKG2D Enhance Î³Î´ T Cellâ€Mediated Lysis of Lymphoma Cells. Scandinavian Journal of Immunology, 2017, 86, 196-206.	2.7	25
61	Stochastics of Cellular Differentiation Explained by Epigenetics: The Case of Tâ€Cell Differentiation and Functional Plasticity. Scandinavian Journal of Immunology, 2017, 86, 184-195.	2.7	8
62	The Ambiguous Role of Î³Î´ T Lymphocytes in Antitumor Immunity. Trends in Immunology, 2017, 38, 668-678.	6.8	82
63	Immunosurveillance by human Î³Î´ T lymphocytes: the emerging role of butyrophilins. F1000Research, 2017, 6, 782.	1.6	20
64	Butyrophilin 3A/CD277â€“Dependent Activation of Human Î³Î´ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations. Journal of Immunology, 2016, 197, 3059-3068.	0.8	40
65	Human Î³Î´ T cells: From a neglected lymphocyte population to cellular immunotherapy: A personal reflection of 30years of Î³Î´ T cell research. Clinical Immunology, 2016, 172, 90-97.	3.2	17
66	Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. Pancreatology, 2016, 16, 1069-1079.	1.1	28
67	Human VÎ´2 T cells are a major source of interleukin-9. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12520-12525.	7.1	68
68	NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human Î³Î´ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors. OncoImmunology, 2016, 5, e1093276.	4.6	63
69	Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells. Oncotarget, 2016, 7, 64743-64756.	1.8	18
70	Editorial: â€œRecent advances in gamma/delta T cell biology: new ligands, new functions, and new translational perspectivesâ€• Frontiers in Immunology, 2015, 6, 371.	4.8	31
71	Intracellular pathways following uptake of bevacizumab in RPE cells. Experimental Eye Research, 2015, 131, 29-41.	2.6	33
72	Modulation of human gamma/delta T-cell activation and phenotype by histone deacetylase inhibitors. Cellular Immunology, 2015, 296, 50-56.	3.0	26

#	Article	IF	Citations
73	Novel synthesis of fluorochrome-coupled zoledronate with preserved functional activity on gamma/delta T cells and tumor cells. MedChemComm, 2015, 6, 919-925.	3.4	3
74	Subcellular localization and activation of ADAM proteases in the context of FasL shedding in T lymphocytes. Molecular Immunology, 2015, 65, 416-428.	2.2	33
75	Î³Î´ T cell activation by bispecific antibodies. Cellular Immunology, 2015, 296, 41-49.	3.0	54
76	Processing of CD74 by the Intramembrane Protease SPPL2a Is Critical for B Cell Receptor Signaling in Transitional B Cells. Journal of Immunology, 2015, 195, 1548-1563.	0.8	25
77	Lysosomeâ€Related Effector Vesicles in T Lymphocytes and <scp>NK</scp> Cells. Scandinavian Journal of Immunology, 2015, 82, 235-243.	2.7	28
78	Î³Î´ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?. OncoImmunology, 2015, 4, e1006088.	4.6	39
79	Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against Î³Î´ T cell cytotoxicity. OncoImmunology, 2015, 4, e988460.	4.6	41
80	Increased co-expression of the natural killer cell receptor NKG2D and further natural killer cell receptors on CD4â¸ T cells in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2015, 33, S-183-4.	0.8	14
81	Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2014, 9, e94357.	2.5	70
82	Inhibition of Human Î³Î´ <scp>T</scp> Cell Proliferation and Effector Functions by Neutrophil Serine Proteases. Scandinavian Journal of Immunology, 2014, 80, 381-389.	2.7	16
83	Monitoring Circulating ÃŽÂ³ÃŽÂ´ T Cells in Cancer Patients to Optimize ÃŽÂ³ÃŽÂ´ T Cell-Based Immunotherapy. Frontiers in Immunology, 2014, 5, 643.	4.8	34
84	Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood Î³Î´ T cells. Cellular and Molecular Life Sciences, 2014, 71, 2335-2346.	5.4	56
85	Phenotype and regulation of immunosuppressive VÎ´2-expressing Î³Î´ T cells. Cellular and Molecular Life Sciences, 2014, 71, 1943-1960.	5.4	76
86	Novel Bispecific Antibodies Increase Î³Î´ T-Cell Cytotoxicity against Pancreatic Cancer Cells. Cancer Research, 2014, 74, 1349-1360.	0.9	133
87	When neutrophils meet T cells: Beginnings of a tumultuous relationship with underappreciated potential. European Journal of Immunology, 2014, 44, 627-633.	2.9	77
88	Cell Fate Decisions Regulated by K63 Ubiquitination of Tumor Necrosis Factor Receptor 1. Molecular and Cellular Biology, 2014, 34, 3214-3228.	2.3	35
89	The CD3 Conformational Change in the Î³Î´ T Cell Receptor Is Not Triggered by Antigens but Can Be Enforced to Enhance Tumor Killing. Cell Reports, 2014, 7, 1704-1715.	6.4	47
90	Identification of SH3 Domain Proteins Interacting with the Cytoplasmic Tail of the A Disintegrin and Metalloprotease 10 (ADAM10). PLoS ONE, 2014, 9, e102899.	2.5	26

#	Article	IF	Citations
91	Generation of Soluble <scp>NKG</scp>2<scp>D</scp> Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications. Scandinavian Journal of Immunology, 2013, 78, 120-129.	2.7	163
92	Regulatory functions of Î³Î´ T cells. International Immunopharmacology, 2013, 16, 382-387.	3.8	31
93	Defining the nature of human Î³Î´ T cells: a biographical sketch of the highly empathetic. Cellular and Molecular Immunology, 2013, 10, 21-29.	10.5	139
94	Shedding of endogenous MHC class Iâ€•related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the â€œa disintegrin and metalloproteasesâ€•10 and 17. International Journal of Cancer, 2013, 133, 1557-1566.	5.1	170
95	Can peripheral blood Î³Î´ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. Journal of Bone and Mineral Research, 2013, 28, 728-735.	2.8	63
96	Human VÎ´2 versus non-VÎ´2 Î³Î´ T cells in antitumor immunity. OncoImmunology, 2013, 2, e23304.	4.6	58
97	The Multifunctionality of Human VÎ³9VÎ´2 Î³Î´ T Cells: Clonal Plasticity or Distinct Subsets?. Scandinavian Journal of Immunology, 2012, 76, 213-222.	2.7	60
98	Regulation of T cell activation by TLR ligands. European Journal of Cell Biology, 2011, 90, 582-592.	3.6	72
99	Î³Î´ T-cells: cross-talk between innate and adaptive immunity. Cellular and Molecular Life Sciences, 2011, 68, 2331-2333.	5.4	34
100	Modulation of Î³Î´ T cell responses by TLR ligands. Cellular and Molecular Life Sciences, 2011, 68, 2357-2370.	5.4	110
101	Aminobisphosphonates and Toll-Like Receptor Ligands: Recruiting Vγ9Vδ2 T Cells for the Treatment of Hematologic Malignancy. Current Medicinal Chemistry, 2011, 18, 5206-5216.	2.4	17
102	Immune Suppression by Î³Î´ T-cells as a Potential Regulatory Mechanism After Cancer Vaccination With IL-12 Secreting Dendritic Cells. Journal of Immunotherapy, 2010, 33, 40-52.	2.4	42
103	Differential but Direct Abolishment of Human Regulatory T Cell Suppressive Capacity by Various TLR2 Ligands. Journal of Immunology, 2010, 184, 4733-4740.	0.8	66
104	Human gamma delta T lymphocytes for immunotherapeutic strategies against cancer. F1000 Medicine Reports, 2010, 2, .	2.9	9
105	gammadelta T-cells: basic features and potential role in vasculitis. Clinical and Experimental Rheumatology, 2010, 28, 104-9.	0.8	1
106	Toll-like Receptors 3 and 7 Agonists Enhance Tumor Cell Lysis by Human Î³Î´ T Cells. Cancer Research, 2009, 69, 8710-8717.	0.9	90
107	Tollâ€Like Receptor Expression and Function in Subsets of Human Î³Î´ T Lymphocytes. Scandinavian Journal of Immunology, 2009, 70, 245-255.	2.7	80
108	Small Molecules for the Activation of Human γ δ T Cell Responses Against Infection. Recent Patents on Anti-infective Drug Discovery, 2008, 3, 1-9.	0.8	21

#	Article	IF	Citations
109	Lysis of a Broad Range of Epithelial Tumour Cells by Human Î³Î´ T Cells: Involvement of NKG2D ligands and Tâ€cell Receptorâ€versus NKG2Dâ€dependent Recognition. Scandinavian Journal of Immunology, 2007, 66, 320-328.	2.7	212
110	Direct Costimulatory Effect of TLR3 Ligand Poly(I:C) on Human Î³Î´ T Lymphocytes. Journal of Immunology, 2006, 176, 1348-1354.	0.8	150
111	Activation of Vγ9Vδ2 T Cells by NKG2D. Journal of Immunology, 2005, 175, 2144-2151.	0.8	282
112	Characterization of Tumor Reactivity of Human Vγ9Vδ2 Î³Î´ T Cells In Vitro and in SCID Mice In Vivo. Journal of Immunology, 2004, 173, 6767-6776.	0.8	164
113	Why not work on T and NK cells in the Kunkel laboratory?. Lupus, 2003, 12, 195-199.	1.6	0
114	Differentiation of Resting Human Peripheral Blood Î³Î´ T Cells toward Th1- or Th2-Phenotype. Cellular Immunology, 2001, 212, 110-117.	3.0	131
115	Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene, 2001, 20, 1193-1202.	5.9	140
116	Cell-surface expression of transrearranged Vγ3-Cδ2 T-cell receptor chains in healthy donors and in ataxia telangiectasia patients. British Journal of Haematology, 2000, 109, 201-210.	2.5	15
117	Regulation of activation-induced cell death of mature T-lymphocyte populations. Cell and Tissue Research, 2000, 301, 85-99.	2.9	79
118	Role of apoptosis in cardiac allograft vasculopathy. Clinical Research in Cardiology, 2000, 89, IX21-IX23.	1.1	3
119	?? T cells, their T cell receptor usage and role in human diseases. Seminars in Immunopathology, 1999, 21, 55-76.	4.0	20
120	gamma delta T cells, their T cell receptor usage and role in human diseases. Seminars in Immunopathology, 1999, 21, 55-75.	4.0	18
121	Increase in Vδ1+ Î³Î´ T cells in the peripheral blood and bone marrow as a selective feature of HIV-1 but not other virus infections. British Journal of Haematology, 1998, 100, 728-734.	2.5	35
122	Antigen-Induced Death of T-Lymphocytes. Fetal and Pediatric Pathology, 1998, 18, 329-354.	0.3	1
123	Analysis of the TCR Vgamma repertoire in healthy donors and HIV-1- infected individuals. International Immunology, 1998, 10, 1067-1075.	4.0	51
124	Identification of the complete expressed human TCR V gamma repertoire by flow cytometry. International Immunology, 1997, 9, 1065-1072.	4.0	57
125	Differential role of tyrosine phosphorylation in the induction of apoptosis in T cell clones via CD95 or the TCR/CD3-complex. Cell Death and Differentiation, 1997, 4, 403-412.	11.2	8
126	Clonal expansion of Vgamma3/Vdelta3-expressing gammadelta T cells in an HIV-1/2-negative patient with CD4 T-cell deficiency. British Journal of Haematology, 1997, 96, 266-271.	2.5	18

#	Article	IF	Citations
127	Comparative analysis of Î±Î² and Î³Î´ T cell activation byMycobacterium tuberculosis and isopentenyl pyrophosphate. European Journal of Immunology, 1997, 27, 952-956.	2.9	66
128	Antigen-induced death of T-Lymphocytes. Frontiers in Bioscience - Landmark, 1997, 2, d61-77.	3.0	45
129	Activation of human Î³Î´ T-cell by heat-treated mistletoe plant extracts. Immunology Letters, 1996, 52, 69-72.	2.5	26
130	Mycobacteria-reactive Î³Î´ T cells in HIV-infected individuals: lack of VÎ³9 cell responsiveness is due to deficiency of antigen-specific CD4 T helper type 1 cells. European Journal of Immunology, 1996, 26, 557-562.	2.9	49
131	Clonal expansion of Î³Î´ T cells expressing two distinct Tâ€cell receptors. British Journal of Haematology, 1996, 94, 62-64.	2.5	14
132	Rapid quantification of lymphocyte subsets in heterogeneous cell populations by flow cytometry. Cytometry, 1994, 16, 152-159.	1.8	102
133	T cell receptor Î³Î´ repertoire in HIV-1-infected individuals. European Journal of Immunology, 1994, 24, 3044-3049.	2.9	72
134	Primary activation of V gamma 9-expressing gamma delta T cells by Mycobacterium tuberculosis. Requirement for Th1-type CD4 T cell help and inhibition by IL-10. Journal of Immunology, 1994, 152, 4984-92.	0.8	76
135	Life and death of a superantigen-reactive human CD4+ T cell clone: staphylococcal enterotoxins induce death by apoptosis but simultaneously trigger a proliferative response in the presence of HLA-DR+ antigen-presenting cells. International Immunology, 1992, 4, 1381-1388.	4.0	61
136	Immunological studies of Î³Î´ t cells in a case of large granular lymphocyte (LGL) leukemia: Leukemic Î³Î´+ T cells are resistant to growth stimulation in vitro but respond to interferon-Î± treatment in vivo. Leukemia Research, 1992, 16, 1087-1095.	0.8	21
137	T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor gamma delta + T cells. Journal of Immunology, 1991, 146, 35-9.	0.8	142